Donepezil Hydrochloride is an acetylcholinesterase inhibitor indicated for dementia of the Alzheimer's type. We supply it to US manufacturers of tablets and orally disintegrating tablets.
Data from PubChem (CID 5741) and FDA’s substance registry
CAS number
120011-70-3
Molecular formula
C24H30ClNO3
Molecular weight
416.0g/mol
FDA UNII
IUPAC name
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one;hydrochloride
InChIKey
XWAIAVWHZJNZQQ-UHFFFAOYSA-N
- Appearance
- White to off-white powder.
- Solubility
- Freely soluble in chloroform, soluble in water and glacial acetic acid, slightly soluble in ethanol and acetonitrile, and practically insoluble in ethyl acetate and n-hexane.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Exists in several polymorphic and hydrated forms. State the form, since sources file them separately.
On the US market
- Reference product
- AriceptNDA 020690
- Approved ANDAs
- 22 with a marketed product
- Approved forms and strengths
- Tablet 5 mg, 10 mg, 23 mg
- Orally disintegrating tablet 5 mg, 10 mg
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com
Sertraline Hydrochloride
Selective serotonin reuptake inhibitor (SSRI)
CAS 79559-97-0Escitalopram Oxalate
Selective serotonin reuptake inhibitor (SSRI)
CAS 219861-08-2Duloxetine Hydrochloride
Serotonin-norepinephrine reuptake inhibitor (SNRI)
CAS 136434-34-9Bupropion Hydrochloride
Norepinephrine-dopamine reuptake inhibitor
CAS 31677-93-7